Literature DB >> 8549304

Comparative in vitro activity of ciprofloxacin vs 8 antimicrobial agents against nosocomial multiresistant P. aeruginosa strains.

E J Giamarellos-Bourboulis1, P Grecka, H Giamarellou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8549304     DOI： 10.2165/00003495-199500492-00042

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  4 in total

1.  In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.

Authors:  D Voutsinas; T Mavroudis; A Avlamis; H Giamarellou
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

2.  Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V.

Authors:  M Kresken; D Hafner; H Mittermayer; L Verbist; E Bergogne-Bérézin; H Giamarellou; S Esposito; B van Klingeren; F H Kayser; D S Reeves
Journal:  Infection       Date:  1994       Impact factor: 3.553

3.  In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia.

Authors:  J A García-Rodríguez; J E García Sánchez; J L Muñoz Bellido; E García Sánchez; M I García García
Journal:  J Chemother       Date:  1991-06       Impact factor: 1.714

4.  Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa.

Authors:  N Masuda; S Ohya
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191
  4 in total
  1 in total

1.  In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.

Authors:  M Araque; E Velazco
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.